Non-conventional markers of atherosclerosis before and after gastric banding surgery

European Heart Journal

Volumn 30, Issue 12, 2009, Pages 1516-1524

  Hanusch Enserer, Ursula ^a   Zorn, Gerlinde ^b   Wojta, Johann ^b   Kopp, Christoph W ^b   Prager, Rudolf ^b   Koenig, Wolfgang ^c   Schillinger, Martin ^b   Roden, Michael ^d   Huber, Kurt ^a  

^a Wilhelminenhospital   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c UNIVERSITY OF ULM   (Germany)

^d HANUSCH HOSPITAL   (Austria)

Author keywords

Adhesion molecules; Bariatric surgery; CD40 ligand; Gastric banding; Lp PLA2; Morbid obesity; PAI 1

Indexed keywords

C REACTIVE PROTEIN; CD40 LIGAND; CELL ADHESION MOLECULE; CHOLESTEROL; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GELATINASE A; GELATINASE B; GLUCOSE; INSULIN; INTERCELLULAR ADHESION MOLECULE 1; PHOSPHOLIPASE A2;

ADULT; ARTICLE; ATHEROSCLEROSIS; BLOOD PRESSURE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DISEASE MARKER; FEMALE; GASTRIC BANDING; GLUCOSE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; OBESITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK ASSESSMENT; RISK REDUCTION;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ADULT; ATHEROSCLEROSIS; BARIATRIC SURGERY; BIOLOGICAL MARKERS; BODY MASS INDEX; CD40 LIGAND; CELL ADHESION MOLECULES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FEMALE; GLUCOSE TOLERANCE TEST; HUMANS; MALE; MIDDLE AGED; OBESITY, MORBID; RISK FACTORS;

EID: 67651123155     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehp108     Document Type: Article

References (41)

1. Eckel RH, Krauss RM. American Heart Association call to action: obesity is a major risk factor for coronary heart disease. AHA Nutrition Committee. Circulation 1998; 97:2099-2100.
2. Manson JAE, Colditz GA, Stampfer MJ, Willett WC, Rosner B, Monson RR, Speizer FE, Hennekens CH. A prospective study of obesity and risk of coronary heart disease in women. N Engl J Med 1990; 322:882-889.
3. Bonow RO, Eckel RH. Diet, obesity and cardiovascular risk. N Engl J Med 2003; 348:2057-2059.
4. Porte D Jr, Seeley RJ, Woods SC, Baskin DG, Figlewicz DP, Schwartz MW. Obesity, diabetes and the central nervous system. Diabetologia 1998; 41:863-888.
5. Lyon CJ, Law RE, Hsueh WA. Minireview: adiposity, inflammation, and atherogenesis. Endocrinology 2003; 144:2195-2200.
6. Huber K. Plasminogen activator inhibitor type-1 (part one): basic mechanisms, regulation, and role for thromboembolic disease. J Thromb Thrombolysis 2001; 11:183-193.
7. Visser M, Bouter Lm, McQuillan GM, Wener MH, Harris TB. Elevated C-reactive protein levels in overweight and obese adults. Circulation 2002; 105:564-569.
8. Landry DB, Couper LL, Bryant SR, Lindner V. Activation of the NF-kappa B and IkB system in smooth muscle cells after art arterial injury. Introduction of vascular cell adhesion molecule-1 and monocyte chemo attractant protein-1. Am J Pathol 1997; 151:1085-1095.
9. Ballantyne CM, Hoogeveen RC, Bang H, Coresh J, Folsom AR, Heiss G, Sharrett AR. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) Study. Circulation 2004; 109:837-842.
10. Heeschen C, Dimmeler S, Hamm CW, van den Brand MJ, Boersma E, Zeiher AM, Simoons ML; for the CAPTURE Study Investigators. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med 2003; 348:1104-1111.
11. Ueland T, Aukrust P, Yndestad A, Otterdal K, Froland SS, Dickstein K, Kjekshus J, Gullestad L, Damas JK. Soluble CD40 ligand in acute and chronic heart failure. Eur Heart J 2005; 26:1101-1107.
12. Varo N, Vicent D, Libby P, Nuzzo R, Calle-Pascual AL, Bernal MR, Fernandez-Cruz A, Veves A, Jarolim P, Varo JJ, Goldfine A, Horton E, Schönbeck U. Elevated plasma levels of the atherogenic mediator soluble CD40 ligand in diabetic patients: a novel target of thiazolidinediones. Circulation 2003; 107:2664-2669.
13. Shah PK, Galis ZS. Matrix metalloproteinase hypothesis of plaque rupture: players keep piling up but questions remain. Circulation 2001; 104:1878-1880.
14. Pontiroli AE, Folli F, Paganelli M, Micheletto G, Pizzocri P, Vedani P, Luisi F, Perego L, Morabito A, Bressani Doldi S. Laparoscopic gastric banding prevents type 2 diabetes and arterial hypertension and induces their remission in morbid obesity: a 4-year case-controlled study. Diabetes Care 2005; 28:2703-2709.
15. Hanusch-Enserer U, Cauza E, Spak M, Dunky A, Rosen HR, Wolf H, Prager R, Eibl MM. Acute-phase response and immunological markers in morbid obese patients and patients following adjustable gastric banding. Int J Obes 2003; 27: 355-361.
16. Hanusch-Enserer U, Cauza E, Spak M, Endler G, Dunky A, Tura A, Wagner O, Rosen HR, Pacini G, Prager R. Improvement of the insulin resistance syndrome and early endothelial dysfunction in morbidly obese patients following 12 months gastric banding. Obes Res 2004; 12:284-291.
17. Buchwald H, Williams SE. Bariatric surgery worldwide 2003. Obes Surg 2004; 14:1157-1164.
18. Sjostrom L, Narbo K, Sjostorm CD, Karason K, Larsson B, Wedel H, Lystig T, Sullivan M, Bouchard C, Carlsson B, Bengtsson C, Dahlgren S, Gummesson A, Jacobson P, Karlsson J, Lindroos AK, Linroth H, Naslund I, Olbers T, Stenlof K, Torgerson J, Agren G, Carlsson LM; Swedish Obese Subjects Study. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 2007; 357: 741-752.
19. Matthews DR, Hosker JP, Rudensky AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentration in man. Diabetologia 1985; 28:412-419.
20. Schönbeck U, Varo N, Libby P, Buring J, Ridker PM. Soluble CD40L and cardiovascular risk in women. Circulation 2001; 104:2266-2268.
21. Koenig W, Khusyinova N, Lowel H, Trischler G, Meisinger C. Lipoprotein-associated phospholipase A2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population: results from the 14-year follow-up of a large cohort from southern Germany. Circulation 2004; 110:1903-1908.
22. Marx N, Froehlich J, Siam L, Ittner J, Wierse G, Schmidt A, Scharnagl H, Hombach V, Koenig W. Antidiabetic PPAR gamma activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease. Arterioscler Thromb Vasc Biol 2003; 23:283-288.
23. Sjostrom L, Lindroos AK, Peltonen M, Torgerson J, Bouchard C, Carlsson B, Dahlgren S, Larsson B, Narbro K, Sjostrom CD, Sullivan M, Wedel H; Swedish Obese Subjects Study Scientific Group. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 2004; 351:2683-2693.
24. Apple FS, Wu AHB, Mair J, Ravkilde J, Panteghini M, Tante J, Pagani F, Christenson RH, Mockel M, Danne O, Jaffe AS. Future biomarkers for detection of ischemia and risk stratification in acute coronary syndrome. Clin Chem 2005;51: 810-824.
25. Esposito K, Pontillo A, Di Polo C, Giugliano G, Masella M, Marfella R, Giugliano D. Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trail. JAMA 2003; 289:1799-1804.
26. Loskutoff DJ, Samad F. The adipocyte and haemostatic balance in obesity: studies of PAI-1. Arterioscler Thromb Vasc Biol 1998; 18:1-6.
27. Lau DCW, Bikramjit D, Hongjun Y, Szmitko PE, Subdodh V. Adipokines: molecular links between adiposity and atherosclerosis. Am J Physiol Heart Circ Physiol 2005; 288:H2031-H2041.
28. Krebs M, Polak K, Vales A, Geiger M, Schmetterer L, Wagner OF, Waldhäusl W, Binder BR, Roden M. Increased plasma levels of plasminogen activator inhibitor-1 and soluble vascular cell adhesion molecule after triacylglycerol infusion in man. Thromb Haemost 2003; 90:422-428.
29. Altman R. Risk factors in coronary atherosclerosis athero-inflammatory meeting point. Thromb J 2003; 1:4.
30. Shirai K. Obesity as the core of the metabolic syndrome and the management of coronary heart disease. Curr Med Res Opin 2004; 20:295-304.
31. Ito H, Ohsima A, Inoue M, Ohto N, Nakasuga K, Kaji Y, Maruyam T, Nishioka K. Weight reduction decreases soluble cellular adhesion molecules in obese women. Clin Exp Pharmacol Physiol 2002; 29:399-404.
32. Ziccardi P, Nappo F, Giugliano G, Esposito K, Marfella R, Cioffi M, Dàndrea F, Molinari AM, Giugliano D. Reduction of inflammatory cytokine concentrations and improvement of endothelial functions in obese women after weight loss over one year. Circulation 2002; 105:804-809.
33. Yang EH, Mc Connell JP, Lennon RJ, Barsness GW, Pumper G, Hartman SJ, Rihal CS, Lerman LO, Lerman A. Lipoprotein-associated phospholipase A2 is an independent marker for coronary endothelial dysfunction in humans. Arterioscler Thromb Vasc Biol 2006; 26:106-111.
34. Kardys I, Oei HH, van der Meer IM, Hofmann A, Breteler MM, Witteman JC. Lipoprotein-associated phopholipase A2 and measures of extracoronary atherosclerosis. The Rotterdam study. Arterioscler Thromb Vasc Biol 2006; 26:631-636.
35. Iribarren C. Lipoprotein-associated phospholipase A2 and cardiovascular risk. Arterioscler Thromb Vasc Biol 2006; 26:5-6.
36. Freedman JE. CD40 ligand-assessing risk instead of damage? N Engl J Med 2003; 348:1163-1165.
37. Cipollone F, Chiarelli F, Davi G, Ferri C, Desideri G, Fazia M, Iezzi A, Santilli F, Pini B, Cuccurullo C, Tumini D, Del Ponte A, Santucci A, Cuccurullo F, Mezzetti A. Enhanced soluble CD40 ligand contributes to endothelial cell dysfunction in vitro and monocyte activation in patients with diabetes mellitus: effect of improved metabolic control. Diabetologia 2005; 48:1216-1224.
38. Verma S, Wang CH, Li SH, Lonn E, Charbonneau F, Title LM, Anderson TJ; FATE Investigators. The relationship between soluble CD40 ligand levels and Framingham coronary heart disease risk score in healthy volunteers. Atherosclerosis 2005; 182:361-365.
39. Blankenberg S, Rupprecht HJ, Poirier O, Bickel C, Smieja M, Hafner G, Meyer J, Cambien F, Tiret L; AtheroGene Investigators. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation 2003; 107:1579-1585.
40. Noji Y, Kajinami K, Kawashiri MA, Todo Y, Horita T, Nohara A, Higashikata T, Inazu A, Koizumi J, Takegoshi T, Mabuchi H. Circulating matrix metalloproteinases and their inhibitors in premature coronary atherosclerosis. Clin Chem Lab Med 2001; 39:380-384.
41. Laimer M, Kaser S, Kranebitter M, Sandhofer A, Muhlmann G, Schwelberger H, Weiss H, Patsch JR, Ebenbichler CF. Effect of pronounced weight loss on the nontraditional cardiovascular risk marker matrix metalloproteinase-9 in middle-aged morbidly obese women. Int J Obes Relat Metab Disord 2005; 29:498-501.